The SomaSignal®
CardioDMTM test

Identify patients with type 2 diabetes more likely to experience a major acute cardiovascular event.*

Enable physicians to identify patients more likely to experience a major acute cardiovascular event (MACE)*

Through a single blood sample, our CardioDM test enables physicians to identify patients with type 2 diabetes (T2D) at risk of MACE and implement precision medical treatment, resulting in improved quality of care and fewer life-threatening events, at a lower cost to payers.

Discover the data behind our test

Icon of heart illustration

CardioDM test

Predicts the absolute risk of a cardiovascular event within 4 years with a median time-to-event of about 20 months, for patients over 40, with type 2 diabetes, with or without cardiovascular disease or chronic kidney disease

  • Single blood test (55 µl)
  • 27 protein biomarkers predict 4-year MACE with median time-to-event of about 20 months
  • Discovery and validation in 6,514 patient samples > 30,000 years of follow-up

Cardiovascular disease is the leading cause of death and disability among people with type 2 diabetes1

1 out of 4 people…

Image of U.S.A. with 8% filled with blue color

Only 8%

of Type 2 Diabetic patients are taking guideline recommended cardioprotective (CP) medicines, regardless of their cardiovascular disease risk.2

Icon showing 1 in 3 people statistic


of Type 2 Diabetes patients are at high risk of cardiovascular disease.2

Icon showing brain with waves through it representing a stroke


of people with diabetes will die from some sort of heart disease or stroke – that’s 2x more likely as someone who doesn’t have the condition.4

Icon of heart monitor flat lining

800,000 deaths

More than 800,000 people in the U.S. die from cardiovascular disease each year — that’s 1 in every 3 deaths – and about 160,000 of them occur in people under age 65.5

1. World Heart Federation, International Diabetes Federation, Taking Diabetes to Heart Survey https://world-heart-federation.org/resource/diabetes-cardiovascular-disease-infographic/.
2. Optum-United Health Group. Commercial and Medicare Advantage analysis of cardioprotective medication use in type 2 diabetic patients. Unpublished data analysis. August 2022.
4. American Heart Association and the Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/diabetes/library/features/diabetes-and-heart.html
5. Centers for Disease Control and Prevention, Million Hearts® initiative https://millionhearts.hhs.gov/learn-prevent/cost-consequences.html#:~:text=Approximately%201.5%20million%20

Current standard of care for patients with type 2 diabetes

Icon showing largre stack of money

High-cost cardioprotective (CP) medication to all patients

Treat 60+ patients to avoid 1 MACE

Future standard of care for patients with type 2 diabetes

Icon of test tube and money showing low cost

CardioDM test to all patients

Treat 20+ patients to avoid 1 MACE

What’s at stake?

Research shows there are three key barriers to identifying and and treating patients more likely to experience MACE.

Image of bullseye and arrows that have missed the target

Inaccurate or poor risk-stratification

Image of heart with pills overlaying the image

Patients who should be – or could be – on CP therapy aren’t

Image of equals sign crossed out, symbolizing inequality

Racial and socioeconomic barriers prevent equitable access to care

How CardioDM can help identify members more likely to experience MACE

Patients identified as high risk with the CardioDM test have been shown to have a 43.4% likelihood of a cardiovascular event or death within a 4-year time horizon, with a median time-to-event of about 20 months.6

Current state of care With the CardioDM test
Sub-optimal use of CP medications Targeted/precise use of CP medications
Poor medication adherence to existing therapies Improved adherence through identified urgency
Inefficient, low throughput, and high cost of existing diagnostics, post-symptom development Efficient and high throughput for early detection
Limited biomarker information for physician, patient discussions Holistic and patient-centric biomarker, diagnostic risk
Poor sensitivity to physiological change Highly sensitive to patient behavioral modifications and medication upgrade
5. Williams SA, et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022 Apr 6;14(639):eabj9625. https://www.science.org/doi/10.1126/scitranslmed.abj9625

See the evidence behind the SomaSignal CardioDM test

Get the data

*Major acute cardiovascular event (MACE) is defined as myocardial infarction, stroke, hospitalization for heart failure or all cause death.
SomaSignal® tests are developed and their performance characteristics determined by SomaLogic Operating Co., Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory